All In Biotech

NDA 022536 · Fresenius Kabi USA

Indomethacin

Indomethacin · Injection · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 20, 2026Latest source record: Dec 21, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Mar 17, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

557

100 Phase 3, 44 recruiting

FAERS reports

11,101

9,017 serious, 1,293 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 19, 2026.

Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g when 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly, or pulmonary plethora on chest x-ray. Indomethacin for Injection is a cardiovascular drug indicated: • To close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g. ( 1 )

Mechanism: Although the exact mechanism of action through which indomethacin causes closure of a patent ductus arteriosus is not known, it is believed to be through inhibition of prostaglandin synthesis.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • INDOMETHACIN · INDOMETHACIN EQ 1MG BASE/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Indomethacin" as an intervention, any sponsor and status, largest first.

All 557 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,316
  • fatigue1,063
  • headache978
  • off label use968
  • arthralgia957
  • pain851
  • nausea840
  • diarrhoea837
  • dizziness805
  • vomiting689
  • dyspnoea681
  • asthenia599

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004218
2005264
2006278
2007257
2008266
2009307
2010270
2011371
2012458
2013314
2014280
2015385
2016540
2017466
2018649
2019707
2020583
2021716
2022981
2023843
2024873
2025732
2026342

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Indomethacin* (Indomethacin)

2024 spending

$3.6M

Beneficiaries

124,276

247,264 claims

Per beneficiary

$29

$0.26 per unit

View as table
YearSpending
2020$3,836,873
2021$3,515,006
2022$3,425,921
2023$3,235,993
2024$3,559,363

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,045 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.